Addressing Cardiovascular Outcomes in T2DM: Exploring Novel Strategies

The meeting was designed to provide the participants with new information and perspectives on effective strategies to help patients with diabetes and/or increased cardiovascular risk, reach their treatment goals.

Participants are part of an educational initiative that will provide support to clinicians in their daily clinical management of cardiovascular risk and diabetes. The program provided an optimal balance between updates in forefront science and clinical dialogue. Below educational resources, such as slides and videorecordings are posted as an educational service to participants
 

The educational objectives were to:

• Summarise the epidemiology and pathophysiology of patients at increased cardiovascular riskand diabetes
• Identify key components of renal glucose handling and the contribution of the kidney to glucose homeostasis
• Describe the effect of multiple interventions that currently are deployed for T2D on cardiovascular safety and the currently unmet need on impacting cardiovascular outcomes
• Explain, based on scientific evidence, the effects that SGLT2 inhibiting agents may have on cardiometabolic markers, including lipids, weight gain, risk of hypoglycemia, HbA1c, glucose levels, related markers and cardiovascular outcomes
• Discuss current and future strategies for practical for practical management and interventions to prevent cardiovascular events in multirisk patients

 

CME Accreditation

This Cardio Diabetes Forum: Addressing Cardiovascular Outcomes'in T2DM: Exploring Novel Strategies“ (Ref. 00003947), is accredited by the European Board for Accreditation in Cardiology for 7 CME credit hours (Day #1: 4 CME credit(s) - Day #2: 3 CME credit(s)). Each participant should claim only those hours of credit that have actually been spent in the educational activity
 

Funding

The programme is supported by an educational grant from Boehringer-Ingelheim (S) Pte Ltd
 

Teaching slides

 

Managing cardiovascular disease in diabetes: Why is it so important

Presentation prepared and held by Prof Kausik Ray, Imperial College London at the CME accredited 'Asian Cardio Diabetes Forum' held on April 23-24, 2016 in Kuala Lumpur, Malaysia.
 

Strategies targeting CV outcomes in diabetes: What have we learned so far?

Presentation prepared and held by Prof Naveed Sattar, University of Glasgow, United Kingdom at the CME accredited 'Asian Cardio Diabetes Forum' held on April 23-24, 2016 in Kuala Lumpur, Malaysia.
 

A review of potential therapeutic targets impacting CV outcomes in T2DM

Presentation prepared and held by Prof Naveed Sattar, University of Glasgow, United Kingdom at the CME accredited 'Asian Cardio Diabetes Forum' held on April 23-24, 2016 in Kuala Lumpur, Malaysia

The EMPA-REG OUTCOME trial: Design and results

Presentation prepared and held by Prof David Fitchett, University of Toronto, Canada at the CME accredited 'Asian Cardio Diabetes Forum' held on April 23-24, 2016 in Kuala Lumpur, Malaysia.

SGLT2 inhibition: What are the potential mechanisms for clinical benefit?

Presentation prepared and held by Prof Hiddo Lambers Heerspink, MD, University Medical Centre Groningen, The Netherlands at the CME accredited 'Asian Cardio Diabetes Forum' held on April 23-24, 2016 in Kuala Lumpur, Malaysia.
 

Managing patients with renal disease

Presentation prepared and held by Prof Hiddo Lambers Heerspink, MD, University Medical Centre Groningen, The Netherlands at the CME accredited 'Asian Cardio Diabetes Forum' held on April 23-24, 2016 in Kuala Lumpur, Malaysia.
 

The future of antidiabetic drugs in T2DM and CVD: What can we expect?

Presentation prepared and held by Prof Kausik Ray, Imperial College London at the CME accredited 'Asian Cardio Diabetes Forum' held on April 23-24, 2016 in Kuala Lumpur, Malaysia.
 

Managing patients with heart failure

Presentation prepared and held by Prof David Fitchett, University of Toronto, Canada at the CME accredited 'Asian Cardio Diabetes Forum' held on April 23-24, 2016 in Kuala Lumpur, Malaysia.

Lectures

Saturday, April 23, 2016

Managing cardiovascular disease in diabetes: Why is it so important Prof. Kausik Ray, MD - Imperial College London, London, United Kingdom

Strategies targeting CV outcomes in diabetes: What have we learned so far?

Prof. Naveed Sattar, MD - University of Glasgow, United Kingdom

 

A review of potential therapeutic targets impacting CV outcomes in T2DM Prof Naveed Sattar, MD, University of Glasgow, United Kingdom

 

The EMPA-REG OUTCOME trial: Design and results Prof. David Fitchett, MD - University of Toronto, Canada

SGLT2 inhibition: What are the potential mechanisms for clinical benefit? Prof. Hiddo Lambers Heerspink, MD - University Medical Centre Groningen, The Netherlands

Managing patients with heart failure Prof. David Fitchett, MD - University of Toronto, Canada

Managing patients with renal disease Prof. Hiddo Lambers Heerspink, MD - University Medical Centre Groningen, The Netherlands

The future of antidiabetic drugs in T2DM and CVD: what can we expect Prof. Kausik Ray, MD - Imperial College London, London, United Kingdom

3 minute education • 10-5-2016, , David Fitchett, MD, University of Toronto, Canad

The EMPA REG Outcome trial: The challenge for cardiologists in managing T2DM

Dr Fitchett provides his perspective on the potential impact of the EMPA REG outcomes trial on the management of T2DM by cardiologists.

3 minute education • 10-5-2016, Kuala Lumpur, Malaysia, Prof Hiddo Lambers Heerspink, Groningen, The Netherlands

CV protection by SGLT2 inhibition: Potential mechanisms for benefit

Prof Lambers Heerspink reviews potential mechanisms beyond glucose lowering, explaining the positive cardiovascular outcomes of SGLT2 inhibition as seen in the EMPA REG Outcomes trial.